INT132717

Context Info Confidence 0.50 First Reported 2005 Last Reported 2009 Negated 1 Speculated 1 Reported most in Body Documents 3 Total Number 4 Disease Relevance 1.27 Pain Relevance 0.03

cell differentiation (PAX5) nucleus (PAX5) DNA binding (PAX5)

Anatomy Link Frequency Urine 2 PAX5 (Homo sapiens)

Pain Link Frequency Relevance Heat fibrosis 1 63.48 Inflammation 5 38.16 abdominal pain 1 37.04 backache 2 22.64 cva 9 5.00 corticosteroid 8 5.00 withdrawal 6 5.00 Bioavailability 5 5.00 Potency 5 5.00 rheumatoid arthritis 4 5.00

Disease Link Frequency Relevance Heat Hypercalcemia 21 100.00 Endometriosis (extended) 19 82.16 Frailty 16 81.04 Osteoporosis 128 78.24 Disorder Of Lipid Metabolism 21 71.44 Endometrial Cancer 7 69.08 Fibrosis 1 63.48 Postmenopausal Osteoporosis 21 62.64 Disease 9 61.40 INFLAMMATION 5 38.16

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Pre- and post-treatment samples were analyzed for urinary excretion of deoxypyridinoline (DPD)/creatinine (Cr), a marker of bone resorption, and serum bone specific alkaline phosphatase (BSAP), a marker of bone formation.

Spec (analyzed) Localization (excretion) of BSAP associated with hypercalcemia

1) Confidence 0.50 Published 2005 Journal Int J Clin Pharmacol Res Section Abstract Doc Link 16402634 Disease Relevance 0.58 Pain Relevance 0

At the same time serum and urine samples were obtained for baseline measurement of markers of bone turnover (serum BSAP and urinary excretion of cross-linked n-terminal telopeptides of type 1 collagen).

Localization (excretion) of BSAP in urine

2) Confidence 0.47 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.12 Pain Relevance 0

Urine NTx, a marker of bone resorption, decreased by comparison with baseline by 73.4%, 71.3%, and 74.9% in the weekly, twice weekly, and daily groups while the equivalent decreases in BSAP were 40.1%, 41.7%, and 43.1%.

Localization (decreases) of BSAP in Urine associated with hypercalcemia

3) Confidence 0.44 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.38 Pain Relevance 0

There were no significant reported decreases in serum bone-specific alkaline phosphatase (BSAP) with 14 days of lasofoxifene treatment.

Neg (no) Localization (decreases) of BSAP

4) Confidence 0.06 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773750 Disease Relevance 0.20 Pain Relevance 0.03

General Comments

This test has worked.